1.878 hasil
Menampilkan 1–20 · 0,18 detik · RSS
Breast
Scopus
ISSN 1532-3080 · Elsevier · 1.878 artikel di indeks
-
Artikel Jurnal
The trajectory of fatigue over time in breast cancer patients treated with chemotherapy: exploring the effect of anthracycline-based chemotherapy
Background: Cancer-related fatigue is a common and profound side effect of cancer treatment. The specific impacts of different classes of chemotherapy remains understudied. This study aimed to compare the trajectory of fatigue between breast cancer patients treated with anthracycline-based versus…
-
Artikel Jurnal
Secondary dry eye disease in breast cancer patients: a pilot study
Purpose: To investigate ocular surface alterations associated with oncological therapy in patients with hormone receptor-positive (HR+) breast cancer. Methods: In this prospective pilot study, 30 HR + breast cancer patients and 10 age-matched healthy controls were evaluated at three time points…
-
Artikel Jurnal
Omission of sentinel lymph node biopsy in early stage luminal breast cancer: impact on adjuvant CDK4/6 inhibitor recommendation and oncological outcomes
Background: Sentinel lymph node biopsy (SLNB) omission is safe in many patients with small, clinically and imaging node-negative (cN0/iN0), hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer (BC). However, recruitment of the pivotal SOUND/INSEMA…
-
Artikel Jurnal
Validation of a deep learning-based AI model for breast cancer risk stratification in postmenopausal ER+/HER2-breast cancer patients
Background: Breast cancer prognostication is crucial for treatment decisions, and the Nottingham Histologic Grade (NHG) system is widely used. However, NHG suffers from interobserver variability, and its division into three risk groups leaves the intermediate group (comprising ∼50 % of patients)…
-
Artikel Jurnal
Large-scale meta-analysis and precision functional assays identify FANCM regions in which PTVs confer different risks for ER-negative and triple-negative breast cancer
The breast cancer risk conferred by germline protein truncating variants (PTVs) in known and putative breast cancer genes has been extensively investigated. However, the effect of FANCM PTVs on breast cancer risk remains unclear. Our previous clinical, genetic and functional results on the…
-
Artikel Jurnal
Breaking down the costs for breast cancer: Insights from Sweden's national quality register
Background: With new emerging technologies for diagnostics and treatment for breast cancer, there is a demand for updated breast cancer costs based on current clinical practice. The objectives of this study were to estimate recent societal costs of breast cancer in Sweden and provide…
-
Artikel Jurnal
Impact of treatment response to neoadjuvant chemotherapy on brain metastasis patterns and breast cancer prognosis
Background: Brain metastases (BM) are a major cause of mortality in breast cancer. While pathologic complete response (pCR) after neoadjuvant chemotherapy is associated with favorable survival outcomes, its impact on BM development and prognosis remains unclear. Methods: We retrospectively analyzed…
-
Artikel Jurnal
Early Ki67 change predicts prognosis and supports response-adapted therapy in breast cancer treated with neoadjuvant chemotherapy
Background: Early prediction of response to neoadjuvant chemotherapy (NACT) in breast cancer is critical for optimizing treatment strategies and improving outcomes. This study assessed the prognostic value of early Ki67 change (ΔKi67 %) via on-treatment core needle biopsy (CNB) in stratifying…
-
Artikel Jurnal
Health-related quality of life and fear of recurrence after early breast cancer treatment: Results from a cross-sectional survey
Background: The growing population of breast cancer survivors has raised attention to the long-term effects of treatment and follow-up. This study explored how survivors experience follow-up care and its impact on quality of life, focusing on fear of cancer recurrence (FCR), work and financial…
-
Artikel Jurnal
A UK study of the experiences, information needs and attitudes to clinical research among patients living with secondary breast cancer in the UK: A prospective co-developed study
Background: Clinical research is key to improving the outcomes of patients with metastatic breast cancer (MBC). However, participation is low, with little data on patients’ attitudes and experiences of clinical research. This study aimed to explore the experience and attitude of patients in…
-
Artikel Jurnal
The Breast International Group (BIG) Patient Partnership: Embedding meaningful patient involvement in the design and conduct of breast cancer clinical research
Involving those with a lived experience of the relevant condition in the design of clinical research ensures that studies address real-world needs and priorities, enabling more relevant, ethical, and impactful outcomes. In 2019, the Breast International Group (BIG) established the BIG Patient…
-
Artikel Jurnal
Early termination of clinical trials enrolling patients with breast cancer: Reasons, determinants, and temporal patterns
Background: The occurrence of clinical trial termination before planned completion (or “early termination” [ET]) remains poorly characterized in the breast cancer field. This study investigates the reasons, determinants, and temporal patterns of ET in breast cancer trials. Methods: We conducted a…
-
Artikel Jurnal
Remnant cholesterol inflammatory index for predicting pathological complete response to neoadjuvant therapy in breast cancer: A multicenter external validation study
Background: Pathological complete response (pCR) after neoadjuvant therapy (NAT) is associated with long-term outcomes in breast cancer (BC). The remnant cholesterol inflammatory index (RCII) integrates lipid-related and inflammatory components, but its role in pCR prediction remains unclear…
-
Artikel Jurnal
Performance of large language models in ambiguous treatment scenarios of early breast cancer
Background: Consensus conferences guide treatment where evidence is ambiguous; lacking ground truth, artificial intelligence is unvalidated there. We evaluated concordance between large language models (LLMs) and expert votes at the 2025 St. Gallen International Breast Cancer Conference. Materials…
-
Artikel Jurnal
Analysis of outcomes of nab-paclitaxel compared to other taxanes in early breast cancer: A study revealing the critical role of calendar-time bias in real-world drug comparisons
Objective: To compare long-term survival outcomes of nab-paclitaxel versus other taxanes in early breast cancer and to evaluate the impact of calendar-time bias in real-world studies. Methods: We enrolled 9217 early invasive breast cancer patients (2007–2024) divided into nab-paclitaxel (n = 3860)…
-
Artikel Jurnal
Tucatinib, trastuzumab, and capecitabine as second- or third-line therapy after trastuzumab deruxtecan in HER2-positive metastatic breast cancer: A multicenter retrospective study in France
Trastuzumab deruxtecan (T-DXd) is the current standard second-line therapy for human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC), and it has been recently approved by FDA as first line therapy in combination with pertuzumab, following the results of the…
Menampilkan maksimal 50 halaman. Persempit pencarian dengan filter untuk hasil yang lebih spesifik.